Nurix Therapeutics’ $209 Million Initial Public Offering

Fenwick & West represented Nurix Therapeutics in the offering. Nurix Therapeutics, Inc. (NASDAQ: NRIX), a company developing targeted protein modulation drugs, executed its initial public offering…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Ambrogio Visconti

This content is for Standard 1 Year members only.
Login Join Now